Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Despite statin therapy, residual cardiovascular risk persists in many patients.
• Elevated triglyceride levels (hypertriglyceridemia) are increasingly recognized as a significant independent risk factor for vascular disease.
• Effective management of hypertriglyceridemia is crucial for comprehensive cardiovascular disease prevention.

Purpose of the Study:

• To review the established causal role of elevated triglycerides in vascular risk.
• To discuss emerging and resurgent therapeutic strategies targeting hypertriglyceridemia.
• To evaluate the role of omega-3 fatty acids and other agents in reducing triglyceride levels and cardiovascular risk.

Main Methods:

• Literature review of studies investigating triglyceride levels and cardiovascular events.
• Analysis of clinical trial data on triglyceride-lowering therapies.
• Examination of the mechanisms by which hypertriglyceridemia contributes to atherosclerosis.

Main Results:

• Evidence confirms a direct causal link between high triglyceride levels and increased vascular risk.
• Omega-3 fatty acids are regaining prominence as a therapeutic option for lowering triglycerides.
• Various emerging strategies show promise in addressing this challenging risk factor.

Conclusions:

• Aggressive modification of residual risk factors, particularly hypertriglyceridemia, is essential for effective cardiovascular disease prevention.
• Targeting elevated triglycerides with agents like omega-3 fatty acids represents a key strategy to mitigate residual cardiovascular risk.
• Further research into novel triglyceride-lowering therapies is warranted to improve patient outcomes.